Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to…

By S. Loi, N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Van Eenoo, G. Rouas, P. Francis, J. Crown, E. Hitre and 6 more. Journal of Clinical Oncology, 2013

1,498 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/912d9e34ec0df9db305242433383adced9189bff

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “Expression of PD-L1 by IHC appears to be increased in TBNC relative to that in hormonedriven tumors, and the prognostic importance of TILs in TNBC make the PD-1/PD-L1 axis appealing as a therapeutic target (37, 38).”
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, background): “TILs have been shown to have prognostic value in HER2-positive breast cancer and TN breast cancer.(45,46) Some evidence from subset analyses points to the ability of TILs to predict benefit from anthracycline-only therapy and from trastuzumab therapy in small cohorts of patients with HER2-positive d”
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014, background): “In addition, HER2-positive breast cancer patients with TIL in their pretreatment specimens have shown improved benefit from certain chemotherapeutic regimens (36).”
Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016, background): “However recent evidence has emerged that tumor infiltrating lymphocytes (TILs) present in breast cancer prior to treatment can predict response to therapy and improved prognosis [4, 5].”
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015, methodology): “This correlation was first reported using baseline samples from the BIG 2-98 trial [19] and subsequently independently confirmed in 481 TNBC sample prospectively collected during two phase III adjuvant randomized BC trials [United States Eastern Cooperative Oncology Group (ECOG) trials 2197 and 1199”
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014, methodology): “Wherever possible, TILs were evaluated as a continuous variable (per increasing 10% increments) [7].”
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014, methodology): “Pathologic Assessment Histopathologic analysis of percentage of TILs was performed on a single full-face HE-stained tumor section using criteria described by Denkert et al(3) and Loi et al.(4) iTILs were defined as the percentage of lymphocytes in direct contact with the tumor cells, whereas sTILs w”
PD-L1 Expression in Triple Negative Breast Cancer (2014, positive): “Loi and colleagues recently reported a prognostic role of tumor-infiltrating lymphocytes (TIL) in TNBC in a large prospective clinical trial (6), and in a study looking specifically at CD8þ intratumoral lymphocytes, Liu and colleagues found that TNBC had higher rates of CD8þ T-cell infiltration, whi”